Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
Clinical trial NCT03933449 · COMPLETED
Trial details
- NCT number
- NCT03933449
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-29
- Primary completion
- 2019-02-13
- Enrollment
- 123
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.